amiodarone has been researched along with Encephalopathy, Toxic in 4 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amiodarone is commonly used in the treatment of refractory paroxysmal atrial fibrillation." | 3.76 | Hepatic dysfunction and neurotoxicity in a patient receiving long-term low-dose amiodarone therapy. ( Arkun, A; Birkhahn, RH; Grau, T; Van Deusen, SK, 2010) |
| "A 76-year-old man developed ataxia after taking amiodarone hydrochloride 400 mg orally three times daily for more than two months; the regimen was the intended loading dosage." | 3.75 | Amiodarone-induced neurotoxicity. ( Lugo, AM; Willis, MS, 2009) |
| "Amiodarone is an antiarrhythmic agent inducing adverse effects on the nervous system, among others." | 1.62 | Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro-in vivo extrapolation. ( Algharably, EAE; Di Consiglio, E; Gundert-Remy, U; Kreutz, R; Testai, E, 2021) |
| "To assess the incidence, severity, and spectrum of neurologic toxic effects associated with administration of amiodarone hydrochloride." | 1.35 | Frequency, characteristics, and risk factors for amiodarone neurotoxicity. ( Ahlskog, JE; Orr, CF, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Algharably, EAE | 1 |
| Di Consiglio, E | 1 |
| Testai, E | 1 |
| Kreutz, R | 1 |
| Gundert-Remy, U | 1 |
| Arkun, A | 1 |
| Van Deusen, SK | 1 |
| Grau, T | 1 |
| Birkhahn, RH | 1 |
| Willis, MS | 1 |
| Lugo, AM | 1 |
| Orr, CF | 1 |
| Ahlskog, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery[NCT05780320] | 242 participants (Anticipated) | Observational | 2022-09-19 | Active, not recruiting | |||
| Pragmatic Amiodarone Trial to Reduce Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery[NCT05543278] | Phase 4 | 242 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for amiodarone and Encephalopathy, Toxic
| Article | Year |
|---|---|
Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro-in vivo extrapolation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Area Under Curve; Biological Availability; Brain; Dose- | 2021 |
Hepatic dysfunction and neurotoxicity in a patient receiving long-term low-dose amiodarone therapy.
Topics: Aged, 80 and over; Amiodarone; Ammonia; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Dr | 2010 |
Amiodarone-induced neurotoxicity.
Topics: Aged; Amiodarone; Ataxia; Humans; Male; Neurotoxicity Syndromes; Postural Balance | 2009 |
Frequency, characteristics, and risk factors for amiodarone neurotoxicity.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Diseases; Humans; Male; M | 2009 |
Frequency, characteristics, and risk factors for amiodarone neurotoxicity.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Diseases; Humans; Male; M | 2009 |
Frequency, characteristics, and risk factors for amiodarone neurotoxicity.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Diseases; Humans; Male; M | 2009 |
Frequency, characteristics, and risk factors for amiodarone neurotoxicity.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Diseases; Humans; Male; M | 2009 |